00 per share requirement for 30 consecutive business days.

During any appeal process, shares of the business‘s common share would continue to trade on the NASDAQ Capital Market.. Agenus receives letter from Listing Qualifications Personnel of The NASDAQ CURRENCY MARKETS Agenus Inc. announced today that the business received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC on March 3, 2011 indicating that the business isn’t in compliance with Nasdaq Market Rule 5550 because the bid cost for the company’s common stock has closed below the minimum amount $1.00 per share requirement for 30 consecutive business days. There is no switch in the trading of organization common share on the NASDAQ Capital Marketplace at the moment, and relative to Nasdaq Marketplace Rule 5810, the business has been provided 180 calendar days, or until August 30, 2011, to regain compliance with the Bid Cost Requirement.Based on the planned interim evaluation, which showed that the prespecified noninferiority threshold for intermittent therapy have been met, the info and safety monitoring committee recommended early reporting of results. The longer-than-expected median survival of 9 years for all patients with biochemical proof disease progression supports the need for a decrease in the toxicity of treatment. However, the discovering that overall survival had not been reduced utilizing the study-described intermittent androgen-deprivation approach should not be extrapolated to various other treatment schedules. Furthermore, this trial didn’t address the relevant query of when, or at what PSA level, treatment should be initiated; the PSA level of 3 ng per milliliter used as an eligibility criterion because of this research was chosen to facilitate accrual.